Mikhail

[Insilico Medicine @InSilicoMeds]

🚀 #O3DC is live: Stop scrolling 40 repos

The Open #DrugDiscovery & Development Consortium just dropped its first shared resource:
-115 benchmarks indexed across 10 categories and 15 consortia.
-Live GitHub status checks + honest notes on the caveats papers usually hide.

Open to academics, industry, and independents. Free to join.

Link in the comments

[Insilico Medicine @InSilicoMeds]

Insilico Medicine introduces the Virtual Aging Cell

We think of age as a number. 🔢 Biology doesn’t. 🧬

The Virtual Aging Cell (VAC) is built to explore how cellular states change across time ⏳ and how those changes shape response to intervention.

The goal isn’t just to measure aging. It’s to predict what comes next 🔬
🧵1/5

[Longevity Technology @LongevityTech]

Insilico licenses AI-discovered drug candidate to Menarini
Collaboration focuses on AI-discovered oncology asset in license deal worth $550m – highlights growing significance of AI in drug discovery.
#longevity #investment #epigenetics #healthspan #biotech
https://t.co/xFF44pMNAH

[Science42:DORA @dorawriting]

New manuscript! 🎉
A study from Insilico Medicine, powered by DORA (https://t.co/3xV2OBHxQr), in collaboration with @tiiuae, explores a multi-serotype dengue vaccine. 🦠
Read it here: https://t.co/K2Pz1OtL8V

#DORAWriting #AIWriting #ComputationalBiology #Dengue #Bioinformatics

[Science42:DORA @dorawriting]

Here’s what I got with just a few clicks for Lesch-Nyhan Syndrome:
✅ Genetic basis
✅ Enzyme deficiency & purine metabolism
✅ Clinical manifestations & therapies
Transform your query into fully content with SCIENCE42: DORA!
#DORAWriting #ResearchTools #AIWriting #Science

[Insilico Medicine @InSilicoMeds]

🚀 Insilico Medicine has announced positive topline results from its Phase IIa trial of ISM001-055, a novel drug candidate targeting TNIK (Traf2- and NCK-interacting kinase) for the treatment of idiopathic pulmonary fibrosis (IPF). The trial’s findings indicate that ISM001-055 is safe, well-tolerated, exhibits a favorable pharmacokinetic profile and demonstrates encouraging clinical efficacy, as evidenced by improvements in forced vital capacity (FVC) over a 12-week period; these improvements in lung function metrics offer hope for patients with limited treatment options.

Zuojun Xu, MD, Professor at Peking Union Medical College and the principal investigator of the Phase IIa trial, said: “I am very impressed by the positive results observed in #IPF patients treated with ISM001-055, particularly the encouraging improvement in FVC. It not only reflects ISM001-055’s potential to slow disease progression but also suggests its capability to stop or even reverse it.”

Read the latest from https://t.co/TnKKrb12rl here: https://t.co/48NvkQhe4A

[Insilico Medicine @InSilicoMeds]

The latest from WIRED Middle East 📽 : Dr. Alex Zhavoronkov, the CEO of Insillico Medicine, shares the importance of #AI in the #pharmaceutical industry, and how it can be utilized to advance the field.

See this Instagram video by @wiredme https://t.co/FBOXOUZUcD

[Insilico Medicine @InSilicoMeds]

🏆🏆Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (#IPF) Designed Using #GenerativeAI

Read the full release here https://t.co/xRBtXvfp8A

[Insilico Medicine @InSilicoMeds]

https://t.co/50vSERSA6P

[Insilico Medicine @InSilicoMeds]

Announcing #Sustainability Benchmarking Initiative and New Gen-AI Features of the https://t.co/6xP2u7llox Platform

Learn more: https://t.co/8JMXLf5kOB

[Insilico Medicine @InSilicoMeds]

Upcoming Event Announcement!

To respond to the fast-evolving global landscape, the World Economic Forum will convene the 15th Annual Meeting of the New Champions in Dalian, People’s Republic of China, on 25-27 June 2024.

Learn more here: https://t.co/iU7QLfs8Vh

[Insilico Medicine @InSilicoMeds]

New paper reveals major therapeutic potential of #TNIK target. Insilico’s lead drug is an #AI-designed TNIK inhibitor for #IPF, now in PHII trials. Researchers show that TNIK also has promise in #cancer, #obesity & Alzheimer's & is assoc w/ aging. @ETH https://t.co/HyMk7Y0dTz

[Insilico Medicine @InSilicoMeds]

How #AI is driving new therapeutics to combat #aging and disease - including the development of Insilico's lead AI drug, INS018_055, now in Phase II trials & how the $101 million @xprize Healthspan from @PeterDiamandis is accelerating the process. @forbes https://t.co/31nytylUTv

[Insilico Medicine @InSilicoMeds]

Presenting nach0 - a new #LLM transformer trained on natural language, synthetic route prediction & molecular generation that can answer biomedical questions & synthesize new molecules. From researchers at Insilico & @nvidia. Findings in @ChemicalScience. https://t.co/Xm2tUpnNuK

[Insilico Medicine @InSilicoMeds]

Announcing first-in-patient dose for Insilico's novel, first-in-class #QPCTL inhibitor, ISM8207, being co-developed w/ Fosun Pharma. The drug candidate was designed using Insilico's #genAI platform for the treatment of advanced malignant tumors. #cancer https://t.co/rOtFFEUUST

[Insilico Medicine @InSilicoMeds]

We're headed to the Yale Innovation Summit! Catch Petrina Kamya, Global Head of AI Platforms at Insilico in conversation w/ Matt Truppo, Global Head of Research Platforms @Sanofi discussing the impact of #AI on #pharma on May 30, 9-10am. #yaleinnovation24 https://t.co/2ilboDnoMP

[Insilico Medicine @InSilicoMeds]

Announcing a novel CDK8/19 #cancer inhibitor designed with Insilico's generative #AI chemistry platform. The compound shows strong enzymatic activity & selectivity, favorable ADME properties & oral bioavailability. In the Journal of Medicinal Chemistry. https://t.co/PbexRPEDzW

[Insilico Medicine @InSilicoMeds]

Sept. 4-5, Insilico is headed to #Berlin for the Drug Discovery Innovation Forum from @GbXevents. Petrina Kamya, Ph.D., Global Head of AI Platforms, will present alongside CEOs and industry leaders on transforming drug discovery with #AI & #ML. #DDIF https://t.co/mnUHrUvNR8

[Insilico Medicine @InSilicoMeds]

Insilico Medicine Chief Business Officer Michelle Chen has been named one of this year’s Top 25 Biotechnology Executives by the Healthcare Technology Report, a leading provider of healthcare sector news and research. https://t.co/WixzzuO6WD

[Insilico Medicine @InSilicoMeds]

Insilico founder & CEO @biogerontology is presenting at @AIM_Congress on May 9, a leading investment platform in the Middle East dedicated to igniting positive transformation through investment, about how #AI is driving new breakthroughs in #medicine. https://t.co/LXQq5mGA11